London-based Chiron has closed a £900K seed round led by THENA Capital, with participation from Arāya Ventures. The AI-driven platform enables healthcare organizations to deliver personalized care beyond the clinic by transforming episodic care into a continuous feedback loop between patients and providers. Built as a multi-condition platform, Chiron has expansion into cardiometabolic health, gastrointestinal disorders, and women’s health already underway.
Chiron combines electronic health records, patient-reported outcomes, wearable data, and AI-derived insights to create and continually refine personalized self-management programs for individuals with long-term conditions. Using n-of-1 causal and predictive analytics, the platform continuously measures the impact of every intervention on symptoms, quality of life, and clinical outcomes. Early deployments with a chronic pain population, in partnership with Fibromyalgia UK, demonstrated a 31% improvement in clinical outcomes.
The platform is architected as multi-condition, and Chiron holds UKCA Class I medical device status with extensive NHS integration capabilities.
“As a healthcare professional, I saw first-hand how transformative it is when people are given the right tools, confidence and insights to find what works best for them,” said CEO and co-founder Carron Manning. “The future of healthcare lies in empowering people to take an active role in their own health, supported by an intelligent, integrated and data-driven self-management layer that works alongside clinicians and medical care – not instead of them. This investment enables us to scale that vision – delivering personalised care beyond the clinic, enabling every person to feel confident to manage their own health, while giving clinicians the insight they need to improve efficacy, reduce demand, and extend their reach.”
“Chiron’s team has built an impressive platform that combines robust clinical evidence, advanced AI and deep integration into existing healthcare pathways,” said Tatum Getty, founding general partner at THENA Capital. “At THENA Capital, we believe Chiron is exceptionally well positioned to become a global leader in patient activation and digitally enabled self-management.”
“Chiron is building technology that will reshape preventative care through more personalised and accessible healthcare whilst reducing pressure on health systems,” said Rupa Popat, founder and managing partner at Arāya Ventures.
The investment will support deployment across NHS Integrated Care Boards and Primary Care Networks, as well as building commercial and regulatory foundations for U.S. market entry. Chiron has received funding from Innovate UK and the Medical Research Council and was selected for the Innovate UK Global Business Innovation Programme in Digital Health.
